目的 探讨预后营养指数（PNI）在未治疗前前列腺癌患者预后预测中的价值。 方法 选取2016年5月至2019年11月南通 大学附属海安医院治疗的124例前列腺癌患者作为研究对象，以PNI中位值为截止点，将所有患者分为高PNI组（>50.2，n=62）与低 PNI组（PNI≤50.2，n=62）。分析PNI与患者一般资料及临床病理特征的关系，采用Kaplan⁃Meier 曲线比较两组患者的总生存期。此 外，通过Cox多因素生存分析确定影响前列腺癌患者预后的独立风险因素。 结果 低PNI与未治疗前前列腺癌患者TNM分期（P=0.031） 显著相关，而与患者年龄、吸烟史、术前PSA水平、Gleason评分及治疗方式等因素无相关性。全组患者中位总生存期为43.0个月（范 围：27.6～58.4），Kaplan⁃Meier曲线显示低PNI组患者的总生存期明显短于高PNI组，3年总生存率分别为50.9%与79.9%，差异有统 计学意义(χ２= 10.967，P=0.001)。多因素Cox生存分析结果表明治疗前PNI（HR=3.174，95%CI=1.122～8.978，P=0.029）、Gleason评分 （HR=2.888，95%CI= 1.094～7.625，P=0.032）和TNM分期（HR=3.179，95%CI=1.116～9.058，P=0.032）是影响前列腺癌患者预后的独 立风险因素。 结论 PNI是未治疗前前列腺癌患者的独立预后因素，其可以作为患者预后评估的一项有用指标。

Objective To investigate the prognostic value of prognostic nutritional index (PNI) for prostate cancer patients. Method A total of 124 prostate cancer patients who were treated in Hai'an Hospital Affiliated to Nantong University from May 2016 to November 2019 were included in this study. All patients were divided into high PNI group (> 50.2, n = 62) and low PNI group (≤50.2, n = 62) based on the median value of PNI. The correlation between PNI and clinicopathological features of prostate cancer patients was analyzed, and Kaplan⁃Meier curves were plotted to evaluate the impact of pretreatment PNI on the overall survival of these patients. In addition, the Cox multivariate regression analysis was performed to determine the independent prognostic factors for prostate cancer patients. Result Low PNI was significantly correlated with TNM stage (P=0.031), but not with patient age, smoking history, prostate specific antigen (PSA) level, Gleason score and treatment methods. In this cohort, the median OS of prostate cancer patients was 43.0 months (range: 27.6-58.4). Kaplan⁃Meier survival curve showed that the OS of patients with low PNI was significantly shorter than that of those with high PNI. The 3⁃year OS of two patient groups was 50.9% and 79.9% respectively, with a significantly statistical difference(χ 2=10.967, P=0.001). Multivariate Cox regression analysis revealed that PNI before treatment(HR=3.174, 95%CI=1.122-8.978, P=0.029), Gleason score (HR=2.888, 95%CI=1.094-7.625, P=0.032) and TNM stage (HR=3.179, 95%CI=1.116-9.058, P=0.032) were independent prognostic factors for pretreatment prostate cancer patients. Conclusion PNI is an independent prognostic factor for pretreatment prostate cancer patients, and it might be used as an useful indicator of prognostic assessment.